TA-CD

TA-CD

TA-CD is an active vaccine[1] developed by the Xenova Group which is used to negate the effects of cocaine, making it suitable for use in treatment of addiction. It is created by combining norcocaine with inactivated cholera toxin.

It works in much the same way as a regular vaccine. A large protein molecule attaches to cocaine, which stimulates response from antibodies which destroy the molecule. This also prevents the cocaine from crossing the blood-brain barrier, negating the euphoric high and rewarding effect of cocaine caused from stimulation of dopamine release in the mesolimbic reward pathway. The vaccine does not affect the users "desire" for cocaine, only the physical effects of the drug.[2]

TA-CD also lowers the effect of cocaine on the heart.

See also

  • TA-NIC - Similar nicotine vaccine

References

  1. ^ Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR (July 2005). "Vaccine pharmacotherapy for the treatment of cocaine dependence". Biol. Psychiatry 58 (2): 158–64. doi:10.1016/j.biopsych.2005.04.032. PMID 16038686. http://linkinghub.elsevier.com/retrieve/pii/S0006-3223(05)00493-2. 
  2. ^ "Cocaine vaccine 'stops addiction'". BBC News. 14 June 2004. http://news.bbc.co.uk/2/hi/health/3804741.stm. Retrieved 2009-10-07. 

External links

v · d · eArtificial induction of immunity / Immunization: Vaccines, Vaccination, and Inoculation (J07)
Development

List of vaccine ingredients · Adjuvants · Mathematical modelling · Timeline · Trials

Classes: Inactivated vaccine · Live vector vaccine (Attenuated vaccine, Heterologous vaccine) · Toxoid · Subunit/component / Peptide / Virus-like particle · Conjugate vaccine · DNA vaccination
Administration
Global: GAVI Alliance · Policy · Schedule · Vaccine injury
USA: ACIP · VAERS · VSD · Vaccine court · Vaccines for Children Program
Vaccines
Bacterial

Anthrax · Brucellosis · Cholera# · Diphtheria# · Hib# · Meningococcus# (NmVac4-A/C/Y/W-135, NmVac4-A/C/Y/W-135 - DT, MeNZB) · Pertussis# · Plague · Pneumococcal# (PPSV, PCV) · Tetanus# · Tuberculosis (BCG)# · Typhoid# (Ty21a, ViCPS) · Typhus

combination: DTwP/DTaP
Viral

Adenovirus · Tick-borne encephalitis · Japanese encephalitis# · Flu# (LAIV, H1N1 (Pandemrix)) · Hepatitis A# · Hepatitis B# · HPV (Gardasil, Cervarix) · Measles# · Mumps# (Mumpsvax) · Polio# (Salk, Sabin) · Rabies# · Rotavirus# · Rubella# · Smallpox (Dryvax) · Varicella zoster (chicken pox#, shingles) · Herpes simplex† · Yellow fever#
combination: MMR · MMRV

research: Cytomegalovirus · Epstein-Barr · HIV · Hepatitis C
Protozoan
Malaria · Trypanosomiasis
Schistosomiasis · Hookworm
Other
Controversy
See also
#WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III

M: BAC

bact (clas)

gr+f/gr+a(t)/gr-p(c)/gr-o

drug(J1p, w, n, m, vacc)

M: VIR

virs(prot)/clss

cutn/syst (hppv/hiva, infl/zost/zoon)/epon

drugJ(dnaa, rnaa, rtva, vacc)


Stub icon This vaccine article is a stub. You can help Wikipedia by expanding it.